CJC-1295 + Ipamorelin Blend
Common secretagogue blend reconstituted as a protocol: GHRH (CJC-1295 no DAC) + GHRP (ipamorelin) dosed together 3×/week for synergistic GH release.
Model levels over time
% of sampled peakModel details: CJC-1295 without DAC (Modified GRF 1-29) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Retained historical illustrative timing assumption only; no validated human SC half-life recovered for this specific form.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.48 hours
- Absorption half-life assumed
- 0.12 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Identity/salt ambiguity persists; no-DAC is not the DAC molecule with a different schedule.
- No measured SC F,Tmax or concentration amplitude supports the current curve.
- Relative output must explicitly identify timing assumption.
- FDA CJC-1295 scientific review
Human studies reviewed used DAC active moiety; FDA did not identify human PK for the other nominated forms and records naming/identity ambiguity.
cjc-1295-no-dac-relative-timing-2026-10 · version 1
Model details: Ipamorelin · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Terminal half-life after15min IV infusion in healthy men; extrapolated to SC shape only. SC absorption remains assumed.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 2 hours
- Absorption half-life assumed
- 0.5 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.5 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Vss is not automatically central volume in a two-compartment model.
- Do not use GH Cmax, EC50 or production rate as ipamorelin concentration.
- No substantiated human SC F or matched Cmax/ref-dose/Tmax recovered.
- Gobburu et al.1999 ipamorelin PK/PD
Healthy men,15min IV infusions4.21–140.45nmol/kg: terminal2h,CL0.078L/h/kg,Vss0.22L/kg,linear PK. GH peak0.67h is a separate PD endpoint, not ipamorelin Tmax.
- FDA ipamorelin scientific presentation Oct2024
Regulatory review distinguishes IV human PK and animal nasal data; no SC-route nonclinical PK identified.
ipamorelin-relative-timing-2026-10 · version 1
Different scales · each curve is normalized to its own peak. Compare timing and shape, not concentration or potency.
| Date | Ipamorelin · Relative timing (% of sampled peak) | CJC-1295 without DAC (Modified GRF 1-29) · Relative timing (% of sampled peak) |
|---|---|---|
| W1 | 0 % of sampled peak | 0 % of sampled peak |
| W1 | 1.0744 % of sampled peak | 5.82818e-8 % of sampled peak |
| W2 | 25.0592 % of sampled peak | 0.0293572 % of sampled peak |
| W2 | 0.0633512 % of sampled peak | 4.39521e-13 % of sampled peak |
| W3 | 1.48006 % of sampled peak | 2.21391e-7 % of sampled peak |
| W4 | 34.4274 % of sampled peak | 0.111517 % of sampled peak |
| W4 | 0.0872702 % of sampled peak | 1.66958e-12 % of sampled peak |
| W5 | 2.03887 % of sampled peak | 8.40985e-7 % of sampled peak |
| W6 | 47.0905 % of sampled peak | 0.423613 % of sampled peak |
| W6 | 0.12022 % of sampled peak | 6.34213e-12 % of sampled peak |
| W7 | 2.80866 % of sampled peak | 0.0000031946 % of sampled peak |
| W8 | 63.6627 % of sampled peak | 1.60915 % of sampled peak |
| W8 | 0.16561 % of sampled peak | 2.40914e-11 % of sampled peak |
The chart uses a bounded time grid. Long horizons can miss brief peaks between samples; shorten the horizon to inspect more detail. Chart peaks are sampled values.
Protocol summary
CJC-1295 + Ipamorelin Blend · 8 weeks starting Oct 15, 26
- CJC-1295 without DAC (Modified GRF 1-29) — 300 mcg Every day, weeks 0–8
- Ipamorelin — 300 mcg Every day, weeks 0–8
Protocol overview
- Category
- peptide stack
- Duration
- 8 weeks
- Compounds
- 2
- Tags
- secretagogue, gh, cjc-1295, ipamorelin, blend, peptide
Compounds in this protocol
- CJC-1295 (no DAC) — 0.3 mg, every-day
- Ipamorelin — 0.3 mg, every-day
How to read this protocol
The chart shows available model curves over the 8-week example. Rows whose model is unavailable are retained for context but produce no curve. Read each model’s details for what its line represents; a plotted level does not predict treatment effects or establish a suitable dose.
The peak/trough explorer examines one complete model interval. The single-dose decline explorer is a separate one-dose scenario; it does not calculate this protocol's washout or a safe treatment-change date. The compound comparison shows available model outputs, not equivalent clinical effects.
Educational only. Not medical advice. These examples do not predict individual blood levels.